BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 38602058)

  • 1. Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer.
    Xia Y; Huang CC; Dittmar R; Du M; Wang Y; Liu H; Shenoy N; Wang L; Kohli M
    Oncotarget; 2016 Jun; 7(24):35818-35831. PubMed ID: 27127882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment.
    Widman AJ; Shah M; Frydendahl A; Halmos D; Khamnei CC; Øgaard N; Rajagopalan S; Arora A; Deshpande A; Hooper WF; Quentin J; Bass J; Zhang M; Langanay T; Andersen L; Steinsnyder Z; Liao W; Rasmussen MH; Henriksen TV; Jensen SØ; Nors J; Therkildsen C; Sotelo J; Brand R; Schiffman JS; Shah RH; Cheng AP; Maher C; Spain L; Krause K; Frederick DT; den Brok W; Lohrisch C; Shenkier T; Simmons C; Villa D; Mungall AJ; Moore R; Zaikova E; Cerda V; Kong E; Lai D; Malbari MS; Marton M; Manaa D; Winterkorn L; Gelmon K; Callahan MK; Boland G; Potenski C; Wolchok JD; Saxena A; Turajlic S; Imielinski M; Berger MF; Aparicio S; Altorki NK; Postow MA; Robine N; Andersen CL; Landau DA
    Nat Med; 2024 Jun; 30(6):1655-1666. PubMed ID: 38877116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-genome Mutational Analysis for Tumor-informed Detection of Circulating Tumor DNA in Patients with Urothelial Carcinoma.
    Nordentoft I; Lindskrog SV; Birkenkamp-Demtröder K; Gonzalez S; Kuzman M; Levatic J; Glavas D; Ptashkin R; Smadbeck J; Afterman D; Lauterman T; Cohen Y; Donenhirsh Z; Tavassoly I; Alon U; Frydendahl A; Rasmussen MH; Andersen CL; Lamy P; Knudsen M; Polak P; Zviran A; Oklander B; Agerbæk M; Jensen JB; Dyrskjøt L
    Eur Urol; 2024 May; ():. PubMed ID: 38811314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer and liquid biopsies: Clinical applications and challenges.
    Urabe F; Sumiyoshi T; Tashiro K; Goto T; Kimura T; Kobayashi T
    Int J Urol; 2024 Jun; 31(6):617-626. PubMed ID: 38551314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid biopsy epigenomic profiling for cancer subtyping.
    Baca SC; Seo JH; Davidsohn MP; Fortunato B; Semaan K; Sotudian S; Lakshminarayanan G; Diossy M; Qiu X; El Zarif T; Savignano H; Canniff J; Madueke I; Saliby RM; Zhang Z; Li R; Jiang Y; Taing L; Awad M; Chau CH; DeCaprio JA; Figg WD; Greten TF; Hata AN; Hodi FS; Hughes ME; Ligon KL; Lin N; Ng K; Oser MG; Meador C; Parsons HA; Pomerantz MM; Rajan A; Ritz J; Thakuria M; Tolaney SM; Wen PY; Long H; Berchuck JE; Szallasi Z; Choueiri TK; Freedman ML
    Nat Med; 2023 Nov; 29(11):2737-2741. PubMed ID: 37865722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preanalytical Variables for the Genomic Assessment of the Cellular and Acellular Fractions of the Liquid Biopsy in a Cohort of Breast Cancer Patients.
    Shishido SN; Welter L; Rodriguez-Lee M; Kolatkar A; Xu L; Ruiz C; Gerdtsson AS; Restrepo-Vassalli S; Carlsson A; Larsen J; Greenspan EJ; Hwang ES; Waitman KR; Nieva J; Bethel K; Hicks J; Kuhn P
    J Mol Diagn; 2020 Mar; 22(3):319-337. PubMed ID: 31978562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of 10,478 cancer genomes identifies candidate driver genes and opportunities for precision oncology.
    Kinnersley B; Sud A; Everall A; Cornish AJ; Chubb D; Culliford R; Gruber AJ; Lärkeryd A; Mitsopoulos C; Wedge D; Houlston R
    Nat Genet; 2024 Jun; ():. PubMed ID: 38890488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tissue- and Blood-derived Genomic Biomarkers for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review.
    Van der Eecken K; Vanwelkenhuyzen J; Deek MP; Tran PT; Warner E; Wyatt AW; Kwan EM; Verbeke S; Van Dorpe J; Fonteyne V; Lumen N; De Laere B; Ost P
    Eur Urol Oncol; 2021 Dec; 4(6):914-923. PubMed ID: 34801437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
    Merseburger AS; Waldron N; Ribal MJ; Heidenreich A; Perner S; Fizazi K; Sternberg CN; Mateo J; Wirth MP; Castro E; Olmos D; Petrylak DP; Chowdhury S
    Eur Urol; 2021 Apr; 79(4):519-529. PubMed ID: 33494937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the tumor genomic landscape of aggressive prostate cancer by whole-genome sequencing of tissue or liquid biopsies.
    Weiss S; Lamy P; Rusan M; Nørgaard M; Ulhøi BP; Knudsen M; Kassentoft CG; Farajzadeh L; Jensen JB; Pedersen JS; Borre M; Sørensen KD
    Int J Cancer; 2024 Jul; 155(2):298-313. PubMed ID: 38602058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
    Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
    Tukachinsky H; Madison RW; Chung JH; Gjoerup OV; Severson EA; Dennis L; Fendler BJ; Morley S; Zhong L; Graf RP; Ross JS; Alexander BM; Abida W; Chowdhury S; Ryan CJ; Fizazi K; Golsorkhi T; Watkins SP; Simmons A; Loehr A; Venstrom JM; Oxnard GR
    Clin Cancer Res; 2021 Jun; 27(11):3094-3105. PubMed ID: 33558422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer.
    Necchi A; Cucchiara V; Grivas P; Bratslavsky G; Jacob J; Spiess PE; Sokol ES; Killian JK; Lin D; Ramkissoon S; Huang RSP; Madison RW; Venstrom JM; Schrock AB; Danziger N; Decker B; Gjoerup O; Graf RP; Oxnard GR; Tukachinsky H; Ross JS
    Cancer; 2021 Dec; 127(24):4557-4564. PubMed ID: 34379803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.
    Herberts C; Annala M; Sipola J; Ng SWS; Chen XE; Nurminen A; Korhonen OV; Munzur AD; Beja K; Schönlau E; Bernales CQ; Ritch E; Bacon JVW; Lack NA; Nykter M; Aggarwal R; Small EJ; Gleave ME; ; Quigley DA; Feng FY; Chi KN; Wyatt AW
    Nature; 2022 Aug; 608(7921):199-208. PubMed ID: 35859180
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.